Editas Medicine secured regulatory approval for the Phase 1/2 Strive study of EDIT-401 in Australia and presented preclinical data showing durable effects. The company's cash runway extends into the second half of 2028.
Editas Medicine secured regulatory approval for the Phase 1/2 Strive study of EDIT-401 in Australia and presented preclinical data showing durable effects. The company's cash runway extends into the second half of 2028.